6th Dermatology Drug Development Summit Europe

The Dermatology Drug Development Summit Europe returns for its 6th year as the premier industry forum dedicated to advancing next-generation immunodermatology therapies. With regulatory breakthroughs reshaping the landscape-such as Eli Lilly’s IL-13 inhibitor and LEO Pharma’s topical JAK-I-2024 was a pivotal year for the industry to accelerate innovation.

Join 80+ senior leaders from Sanofi, Alys Pharmaceuticals, Moonlake Immunotherapeutics, and more to ensure 2025 breaks new records for the industry!

Get stuck into topics such as:

- Explore novel clinical and preclinical candidate data to produce best-in-class drugs for diverse indications
- Understand contemporary indication expansion strategies to maximise the value of your pipeline and diversify your immuno-inflammatory portfolio
- Collaborate with peers to accelerate trial timelines, optimize endpoint strategies, and enhance clinical data quality to fast track regulatory approval

Speakers: Ana Rossi, Global Senior Medical Director, Immunology, Sanofi, Carlo Pincelli, Chief Medical Officer, PinCell, Cheri Ackerman, Co-Founder and CEO, Concerto Biosciences, Daniel Brownell, Senior Director, R AND D, AOBiome, Ehsanollah Esfandiari, Global Head, Immunology R AND D, Kyowa Kirin, Eric Meldrum, Chief Scientific Officer, Citryll Therapeutics, Hana Cernecka, Managing director, EB Research Institute, Hannah Cummings, Senior Director, Medical Affairs, Kyowa Kirin, Kristian Reich, Co-Founder and Chief Scientific Officer, MoonLake, Lars French, Chief Medical Officer, Alys Pharmaceuticals, Luis F. Santamaria-Babí, Full Professor of Clinical and Translational Immunology, University of Barcelona, Mike Davies, Chief Executive Officer, Carocell Bio, Niels Riedemann, Chief Executive Officer, Inflarx, Serena Mandla, Co-Founder and Chief Scientific Officer, Noa Therapeutics, Simmi Wiggins, Global Lead, Immunology and Medical, Sanofi, Verena Hultsch, Global Medical Affairs, Dermatology - Bullous Pemphigoid, Sanofi